A new study revealed that the weight loss injection contains the GLP-1 (GLP-1) (GLP-1) (GLP-1) (GLP-1), such as Ozmbek, on which millions of people who aspire to reduce their weight and suffer from diabetes may increase may increase the risk of thyroid cancer during the first year of receiving Treatment.
However, the study indicates that the overall risk of developing thyroid cancer over a period of 6 years of using injections has remained low.
The study was conducted by researchers from the Endocrine, Diabetes, metabolism and nutrition department in Mayo Clinic in the United States, and its results were published in the Gamma Journal of Ear, Throat, Head and Neck Surgery on January 23, and the British Daily Mail was written about it.
The researchers continued more than 350,000 patients, and the study revealed that injections put users at the risk of developing the disease larger compared to 3 other drugs used in the treatment of diabetes.
These results indicate that the start of the GLB-1 remedy was associated with the diagnosis of new cases of thyroid cancer in the short term only, and it is likely that this is due to the increase in the tests conducted and the discovery of cases with the disease and not the injection of cancer. The scientists – who described the results as important – emphasized the need to conduct more research to confirm it.
In 2023 studies conducted on mice and rats revealed that semaglotide – an effective ingredient in injections, Wagofi, and Ozambek – could increase the risk of infection with one type of thyroid cancer, which is Medullary Thyroid Cancer (MTC).